{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:07:13Z","timestamp":1792145233598,"version":"4.4.0"},"reference-count":50,"publisher":"American Association for Cancer Research (AACR)","issue":"15","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Proteasome inhibitors sensitize tumor cells to DNA-damaging agents, including ionizing radiation (IR), and DNA cross-linking agents (melphalan and cisplatin) through unknown mechanisms. The Fanconi anemia pathway is a DNA damage\u2013activated signaling pathway, which regulates cellular resistance to DNA cross-linking agents. Monoubiquitination and nuclear foci formation of FANCD2 are critical steps of the Fanconi anemia pathway. Here, we show that proteasome function is required for the activation of the Fanconi anemia pathway and for DNA damage signaling. Proteasome inhibitors (bortezomib and MG132) and depletion of 19S and 20S proteasome subunits (PSMD4, PSMD14, and PSMB3) inhibited monoubiquitination and\/or nuclear foci formation of FANCD2, whereas depletion of DSS1\/SHFM1, a subunit of the 19S proteasome that also directly binds to BRCA2, did not inhibit FANCD2 monoubiquitination or foci formation. On the other hand, DNA damage\u2013signaling processes, such as IR-induced foci formation of phosphorylated ATM (phospho-ATM), 53BP1, NBS1, BRCA1, FANCD2, and RAD51, were delayed in the presence of proteasome inhibitors, whereas ATM autophosphorylation and nuclear foci formation of \u03b3H2AX, MDC1, and RPA were not inhibited. Furthermore, persistence of DNA damage and abrogation of the IR-induced G1-S checkpoint resulted from proteasome inhibition. In summary, we showed that the proteasome function is required for monoubiquitination of FANCD2, foci formation of 53BP1, phospho-ATM, NBS1, BRCA1, FANCD2, and RAD51. The dependence of specific DNA damage\u2013signaling steps on the proteasome may explain the sensitization of tumor cells to DNA-damaging chemotherapeutic agents by proteasome inhibitors. [Cancer Res 2007;67(15):7395\u2013405]<\/jats:p>","DOI":"10.1158\/0008-5472.can-07-1015","type":"journal-article","created":{"date-parts":[[2007,8,1]],"date-time":"2007-08-01T14:34:13Z","timestamp":1185978853000},"page":"7395-7405","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":188,"title":["Proteasome Function Is Required for DNA Damage Response and Fanconi Anemia Pathway Activation"],"prefix":"10.1158","volume":"67","author":[{"given":"Ce\u0301line","family":"Jacquemont","sequence":"first","affiliation":[{"name":"Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyasu","family":"Taniguchi","sequence":"additional","affiliation":[{"name":"Divisions of Human Biology and Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2007,8,1]]},"reference":[{"key":"2022061623343607900_B1","doi-asserted-by":"crossref","unstructured":"Pickart CM, Cohen RE. Proteasomes and their kin: proteases in the machine age. Nat Rev Mol Cell Biol\u20082004; 5: 177\u201387.","DOI":"10.1038\/nrm1336"},{"key":"2022061623343607900_B2","doi-asserted-by":"crossref","unstructured":"Sigismund S, Polo S, Di Fiore PP. Signaling through monoubiquitination. Curr Top Microbiol Immunol\u20082004; 286: 149\u201385.","DOI":"10.1007\/978-3-540-69494-6_6"},{"key":"2022061623343607900_B3","doi-asserted-by":"crossref","unstructured":"Berkers CR, Verdoes M, Lichtman E, et al. Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib. Nat Methods\u20082005; 2: 357\u201362.","DOI":"10.1038\/nmeth759"},{"key":"2022061623343607900_B4","doi-asserted-by":"crossref","unstructured":"Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer\u20082004; 4: 349\u201360.","DOI":"10.1038\/nrc1361"},{"key":"2022061623343607900_B5","doi-asserted-by":"crossref","unstructured":"Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol\u20082006; 3: 374\u201387.","DOI":"10.1038\/ncponc0555"},{"key":"2022061623343607900_B6","doi-asserted-by":"crossref","unstructured":"Pajonk F, Pajonk K, McBride WH. Apoptosis and radiosensitization of hodgkin cells by proteasome inhibition. Int J Radiat Oncol Biol Phys\u20082000; 47: 1025\u201332.","DOI":"10.1016\/S0360-3016(00)00516-2"},{"key":"2022061623343607900_B7","doi-asserted-by":"crossref","unstructured":"Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood\u20082003; 101: 2377\u201380.","DOI":"10.1182\/blood-2002-06-1768"},{"key":"2022061623343607900_B8","doi-asserted-by":"crossref","unstructured":"Yunmbam MK, Li QQ, Mimnaugh EG, et al. Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells. Int J Oncol\u20082001; 19: 741\u20138.","DOI":"10.3892\/ijo.19.4.741"},{"key":"2022061623343607900_B9","doi-asserted-by":"crossref","unstructured":"Berenson JR, Yang HH, Sadler K, et al. Phase I\/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol\u20082006; 24: 937\u201344.","DOI":"10.1200\/JCO.2005.03.2383"},{"key":"2022061623343607900_B10","doi-asserted-by":"crossref","unstructured":"Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol\u20082005; 23: 5943\u20139.","DOI":"10.1200\/JCO.2005.16.006"},{"key":"2022061623343607900_B11","doi-asserted-by":"crossref","unstructured":"Taniguchi T, D'Andrea AD. Molecular pathogenesis of Fanconi anemia: recent progress. Blood\u20082006; 107: 4223\u201333.","DOI":"10.1182\/blood-2005-10-4240"},{"key":"2022061623343607900_B12","doi-asserted-by":"crossref","unstructured":"Garcia-Higuera I, Taniguchi T, Ganesan S, et al. Interaction of the Fanconi anemia proteins and BRCA1 in a common pathway. Mol Cell\u20082001; 7: 249\u201362.","DOI":"10.1016\/S1097-2765(01)00173-3"},{"key":"2022061623343607900_B13","doi-asserted-by":"crossref","unstructured":"Taniguchi T, Garcia-Higuera I, Andreassen PR, Gregory RC, Grompe M, D'Andrea AD. S-phase-specific interaction of the Fanconi anemia protein, FANCD2, with BRCA1 and RAD51. Blood\u20082002; 100: 2414\u201320.","DOI":"10.1182\/blood-2002-01-0278"},{"key":"2022061623343607900_B14","doi-asserted-by":"crossref","unstructured":"Andreassen PR, D'Andrea AD, Taniguchi T. ATR couples FANCD2 monoubiquitination to the DNA-damage response. Genes Dev\u20082004; 18: 1958\u201363.","DOI":"10.1101\/gad.1196104"},{"key":"2022061623343607900_B15","doi-asserted-by":"crossref","unstructured":"Meetei AR, de Winter JP, Medhurst AL, et al. A novel ubiquitin ligase is deficient in Fanconi anemia. Nat Genet\u20082003; 35: 165\u201370.","DOI":"10.1038\/ng1241"},{"key":"2022061623343607900_B16","doi-asserted-by":"crossref","unstructured":"Machida YJ, Machida Y, Chen Y, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell\u20082006; 23: 589\u201396.","DOI":"10.1016\/j.molcel.2006.06.024"},{"key":"2022061623343607900_B17","doi-asserted-by":"crossref","unstructured":"Nijman SM, Huang TT, Dirac AM, et al. The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway. Mol Cell\u20082005; 17: 331\u20139.","DOI":"10.1016\/j.molcel.2005.01.008"},{"key":"2022061623343607900_B18","doi-asserted-by":"crossref","unstructured":"Krogan NJ, Lam MH, Fillingham J, et al. Proteasome involvement in the repair of DNA double-strand breaks. Mol Cell\u20082004; 16: 1027\u201334.","DOI":"10.1016\/j.molcel.2004.11.033"},{"key":"2022061623343607900_B19","doi-asserted-by":"crossref","unstructured":"Marston NJ, Richards WJ, Hughes D, Bertwistle D, Marshall CJ, Ashworth A. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals. Mol Cell Biol\u20081999; 19: 4633\u201342.","DOI":"10.1128\/MCB.19.7.4633"},{"key":"2022061623343607900_B20","doi-asserted-by":"crossref","unstructured":"Li J, Zou C, Bai Y, Wazer DE, Band V, Gao Q. DSS1 is required for the stability of BRCA2. Oncogene\u20082006; 25: 1186\u201394.","DOI":"10.1038\/sj.onc.1209153"},{"key":"2022061623343607900_B21","doi-asserted-by":"crossref","unstructured":"Gudmundsdottir K, Lord CJ, Witt E, Tutt AN, Ashworth A. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells. EMBO Rep\u20082004; 5: 989\u201393.","DOI":"10.1038\/sj.embor.7400255"},{"key":"2022061623343607900_B22","doi-asserted-by":"crossref","unstructured":"Taniguchi T, Tischkowitz M, Ameziane N, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med\u20082003; 9: 568\u201374.","DOI":"10.1038\/nm852"},{"key":"2022061623343607900_B23","doi-asserted-by":"crossref","unstructured":"Bence NF, Sampat RM, Kopito RR. Impairment of the ubiquitin-proteasome system by protein aggregation. Science\u20082001; 292: 1552\u20135.","DOI":"10.1126\/science.292.5521.1552"},{"key":"2022061623343607900_B24","doi-asserted-by":"crossref","unstructured":"Huang TT, Nijman SM, Mirchandani KD, et al. Regulation of monoubiquitinated PCNA by DUB autocleavage. Nat Cell Biol\u20082006; 8: 339\u201347.","DOI":"10.1038\/ncb1378"},{"key":"2022061623343607900_B25","doi-asserted-by":"crossref","unstructured":"Huang TT, D'Andrea AD. Regulation of DNA repair by ubiquitylation. Nat Rev Mol Cell Biol\u20082006; 7: 323\u201334.","DOI":"10.1038\/nrm1908"},{"key":"2022061623343607900_B26","doi-asserted-by":"crossref","unstructured":"Dantuma NP, Groothuis TA, Salomons FA, Neefjes J. A dynamic ubiquitin equilibrium couples proteasomal activity to chromatin remodeling. J Cell Biol\u20082006; 173: 19\u201326.","DOI":"10.1083\/jcb.200510071"},{"key":"2022061623343607900_B27","doi-asserted-by":"crossref","unstructured":"Borodovsky A, Kessler BM, Casagrande R, Overkleeft HS, Wilkinson KD, Ploegh HL. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J\u20082001; 20: 5187\u201396.","DOI":"10.1093\/emboj\/20.18.5187"},{"key":"2022061623343607900_B28","doi-asserted-by":"crossref","unstructured":"Reuter TY, Medhurst AL, Waisfisz Q, et al. Yeast two-hybrid screens imply involvement of Fanconi anemia proteins in transcription regulation, cell signaling, oxidative metabolism, and cellular transport. Exp Cell Res\u20082003; 289: 211\u201321.","DOI":"10.1016\/S0014-4827(03)00261-1"},{"key":"2022061623343607900_B29","doi-asserted-by":"crossref","unstructured":"Heinrich MC, Silvey KV, Stone S, et al. Posttranscriptional cell cycle-dependent regulation of human FANCC expression. Blood\u20082000; 95: 3970\u20137.","DOI":"10.1182\/blood.V95.12.3970"},{"key":"2022061623343607900_B30","doi-asserted-by":"crossref","unstructured":"Liu Q, Guntuku S, Cui XS, et al. Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint. Genes Dev\u20082000; 14: 1448\u201359.","DOI":"10.1101\/gad.14.12.1448"},{"key":"2022061623343607900_B31","doi-asserted-by":"crossref","unstructured":"Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature\u20082003; 421: 499\u2013506.","DOI":"10.1038\/nature01368"},{"key":"2022061623343607900_B32","doi-asserted-by":"crossref","unstructured":"Lim DS, Kim ST, Xu B, et al. ATM phosphorylates p95\/nbs1 in an S-phase checkpoint pathway. Nature\u20082000; 404: 613\u20137.","DOI":"10.1038\/35007091"},{"key":"2022061623343607900_B33","doi-asserted-by":"crossref","unstructured":"Matsuoka S, Rotman G, Ogawa A, Shiloh Y, Tamai K, Elledge SJ. Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro. Proc Natl Acad Sci U S A\u20082000; 97: 10389\u201394.","DOI":"10.1073\/pnas.190030497"},{"key":"2022061623343607900_B34","doi-asserted-by":"crossref","unstructured":"Ho GP, Margossian S, Taniguchi T, D'Andrea AD. Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance. Mol Cell Biol\u20082006; 26: 7005\u201315.","DOI":"10.1128\/MCB.02018-05"},{"key":"2022061623343607900_B35","doi-asserted-by":"crossref","unstructured":"Binz SK, Sheehan AM, Wold MS. Replication protein A phosphorylation and the cellular response to DNA damage. DNA Repair (Amst)\u20082004; 3: 1015\u201324.","DOI":"10.1016\/j.dnarep.2004.03.028"},{"key":"2022061623343607900_B36","doi-asserted-by":"crossref","unstructured":"Josse L, Harley ME, Pires IM, Hughes DA. Fission yeast Dss1 associates with the proteasome and is required for efficient ubiquitin-dependent proteolysis. Biochem J\u20082006; 393: 303\u20139.","DOI":"10.1042\/BJ20051238"},{"key":"2022061623343607900_B37","doi-asserted-by":"crossref","unstructured":"Xu B, Kastan MB. Analyzing cell cycle checkpoints after ionizing radiation. Methods Mol Biol\u20082004; 281: 283\u201392.","DOI":"10.1385\/1-59259-811-0:283"},{"key":"2022061623343607900_B38","doi-asserted-by":"crossref","unstructured":"Lee JH, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science\u20082005; 308: 551\u20134.","DOI":"10.1126\/science.1108297"},{"key":"2022061623343607900_B39","doi-asserted-by":"crossref","unstructured":"Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer\u20082003; 3: 155\u201368.","DOI":"10.1038\/nrc1011"},{"key":"2022061623343607900_B40","doi-asserted-by":"crossref","unstructured":"Stucki M, Clapperton JA, Mohammad D, Yaffe MB, Smerdon SJ, Jackson SP. MDC1 directly binds phosphorylated histone H2AX to regulate cellular responses to DNA double-strand breaks. Cell\u20082005; 123: 1213\u201326.","DOI":"10.1016\/j.cell.2005.09.038"},{"key":"2022061623343607900_B41","doi-asserted-by":"crossref","unstructured":"Bekker-Jensen S, Lukas C, Melander F, Bartek J, Lukas J. Dynamic assembly and sustained retention of 53BP1 at the sites of DNA damage are controlled by Mdc1\/NFBD1. J Cell Biol\u20082005; 170: 201\u201311.","DOI":"10.1083\/jcb.200503043"},{"key":"2022061623343607900_B42","doi-asserted-by":"crossref","unstructured":"Botuyan MV, Lee J, Ward IM, et al. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell\u20082006; 127: 1361\u201373.","DOI":"10.1016\/j.cell.2006.10.043"},{"key":"2022061623343607900_B43","doi-asserted-by":"crossref","unstructured":"Huyen Y, Zgheib O, Ditullio RA, Jr., et al. Methylated lysine 79 of histone H3 targets 53BP1 to DNA double-strand breaks. Nature\u20082004; 432: 406\u201311.","DOI":"10.1038\/nature03114"},{"key":"2022061623343607900_B44","doi-asserted-by":"crossref","unstructured":"Lou Z, Minter-Dykhouse K, Franco S, et al. MDC1 maintains genomic stability by participating in the amplification of ATM-dependent DNA damage signals. Mol Cell\u20082006; 21: 187\u2013200.","DOI":"10.1016\/j.molcel.2005.11.025"},{"key":"2022061623343607900_B45","doi-asserted-by":"crossref","unstructured":"Wang B, Matsuoka S, Carpenter PB, Elledge SJ. 53BP1, a mediator of the DNA damage checkpoint. Science\u20082002; 298: 1435\u20138.","DOI":"10.1126\/science.1076182"},{"key":"2022061623343607900_B46","doi-asserted-by":"crossref","unstructured":"Wang X, Haber JE. Role of saccharomyces single-stranded DNA-binding protein RPA in the strand invasion step of double-strand break repair. PLoS Biol\u20082004; 2: E21.","DOI":"10.1371\/journal.pbio.0020021"},{"key":"2022061623343607900_B47","doi-asserted-by":"crossref","unstructured":"Sorensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol\u20082005; 7: 195\u2013201.","DOI":"10.1038\/ncb1212"},{"key":"2022061623343607900_B48","doi-asserted-by":"crossref","unstructured":"Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK. The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem\u20082000; 275: 23899\u2013903.","DOI":"10.1074\/jbc.C000276200"},{"key":"2022061623343607900_B49","doi-asserted-by":"crossref","unstructured":"Davies AA, Masson JY, McIlwraith MJ, et al. Role of BRCA2 in control of the RAD51 recombination and DNA repair protein. Mol Cell\u20082001; 7: 273\u201382.","DOI":"10.1016\/S1097-2765(01)00175-7"},{"key":"2022061623343607900_B50","doi-asserted-by":"crossref","unstructured":"Collis SJ, Barber LJ, Clark AJ, Martin JS, Ward JD, Boulton SJ. HCLK2 is essential for the mammalian S-phase checkpoint and impacts on Chk1 stability. Nat Cell Biol\u20082007; 9: 391\u2013401.","DOI":"10.1038\/ncb1555"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7395\/2864832\/7395.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/67\/15\/7395\/2864832\/7395.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,16]],"date-time":"2022-06-16T23:54:28Z","timestamp":1655423668000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/67\/15\/7395\/533397\/Proteasome-Function-Is-Required-for-DNA-Damage"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,8,1]]},"references-count":50,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2007,8,1]]},"published-print":{"date-parts":[[2007,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-07-1015","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22367652.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367652","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495639","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495639.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,8,1]]}}}